NGL Fine-Chem Limited NGLFINE NSEPHARMA

Healthcare · Drug Manufacturers - General · India

https://www.nglfinechem.com

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Market & Price

Market Cap

₹1,720.64 Cr

Current Price

₹2,785.10

High / Low (52W)

₹2,858.90 / ₹993.57

Beta

0.55

Valuation

Stock P/E

35.72

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹485.91

Price to Book

5.73

P/S

3.43

EV/EBITDA

24.55

Dividend Yield

0.06%

Profitability & Returns

ROCE

17.15%

ROE

15.74%

ROA

6.78%

Profit Margin

9.61%

Op Margin

10.96%

EPS (Latest Qtr)

₹21.83

EPS (TTM)

₹77.98

Balance Sheet & Liquidity

Debt/Equity

0.33

Quick Ratio

1.17

Current Ratio

1.84

Debt

₹108.51 Cr

Total Assets

₹545.50 Cr

Current Assets

₹276.39 Cr

Working Capital

₹126.37 Cr

Ownership

Promoter Holding

72.74%

Chg in Prom Hold

FII / Inst Holding

0.00%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹1,784.72 Cr

Total Revenue (TTM)

₹500.95 Cr

EBITDA

₹72.69 Cr

Free Cash Flow

₹-71.40 Cr

Operating Cash Flow

₹43.32 Cr

Shares Outstanding

₹61.78 L

Gross Margin

52.19%

Payout Ratio

2.25%

Growth (CAGR)

Revenue 5Y

22.34%

Profit 5Y

32.91%

Revenue (YoY)

57.20%

Earnings (YoY)

1,539.80%

PROS

Compounding revenue at 22.3% over 5 years.
Profit CAGR of 32.9% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	NGLFINE NGL Fine-Chem Limited NSEPHARMA	2,785.10	35.72	₹1,720.64 Cr	0.06%	17.15%	15.74%	22.34%	32.91%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	89.10 Cr	94.97 Cr	104.19 Cr	120.26 Cr	127.51 Cr	149.23 Cr
Cost of Revenue	-	43.53 Cr	47.80 Cr	51.89 Cr	57.27 Cr	59.51 Cr	70.90 Cr
Gross Profit	-	45.57 Cr	47.17 Cr	52.29 Cr	62.99 Cr	68.00 Cr	78.33 Cr
Operating Expenses	-	43.57 Cr	44.17 Cr	45.59 Cr	50.92 Cr	50.87 Cr	61.97 Cr
Operating Income	-	2.00 Cr	3.00 Cr	6.71 Cr	12.07 Cr	17.13 Cr	16.36 Cr
EBITDA	-	4.96 Cr	5.35 Cr	17.33 Cr	19.21 Cr	26.93 Cr	23.87 Cr
Interest Expense	-	60.05 L	97.36 L	1.22 Cr	1.16 Cr	1.07 Cr	1.01 Cr
Pretax Income	-	1.27 Cr	1.06 Cr	11.84 Cr	12.96 Cr	20.67 Cr	17.81 Cr
Tax Provision	-	-1.13 L	51.65 L	2.60 Cr	3.34 Cr	4.98 Cr	4.33 Cr
Net Income	-	1.28 Cr	54.36 L	9.24 Cr	9.63 Cr	15.69 Cr	13.49 Cr
Diluted EPS	15.88	2.07	0.88	14.96	15.58	25.40	21.83

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	273.57 Cr	333.71 Cr	368.26 Cr	500.95 Cr
Cost of Revenue	-	140.32 Cr	158.69 Cr	182.41 Cr	239.49 Cr
Gross Profit	-	133.25 Cr	175.03 Cr	185.85 Cr	261.46 Cr
Operating Expenses	-	109.59 Cr	132.93 Cr	164.43 Cr	208.36 Cr
Operating Income	-	23.67 Cr	42.10 Cr	21.42 Cr	53.11 Cr
EBITDA	-	39.85 Cr	67.40 Cr	42.50 Cr	87.42 Cr
Interest Expense	-	1.20 Cr	1.34 Cr	2.33 Cr	4.47 Cr
Pretax Income	-	27.36 Cr	54.42 Cr	27.71 Cr	63.37 Cr
Tax Provision	-	6.87 Cr	13.10 Cr	6.59 Cr	15.24 Cr
Net Income	-	20.50 Cr	41.32 Cr	21.12 Cr	48.13 Cr
Diluted EPS	80.77	33.18	66.88	34.19	-

Compounded Sales Growth

5 Years:	22.34%
1 Year:	57.20%

Compounded Profit Growth

5 Years:	32.91%
1 Year:	1,539.80%

Stock Price Performance

1 Year:	+140.09%
6 Months:	+110.82%
3 Months:	+23.26%
1 Month:	+22.06%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	287.08 Cr	355.54 Cr	433.39 Cr	545.50 Cr
Current Assets	-	162.66 Cr	212.67 Cr	235.38 Cr	276.39 Cr
Cash & Equivalents	-	7.83 Cr	39.52 L	58.33 L	2.81 Cr
Inventory	-	26.99 Cr	43.30 Cr	51.27 Cr	70.28 Cr
Receivables	-	65.87 Cr	89.62 Cr	81.55 Cr	130.88 Cr
Total Liabilities	-	64.53 Cr	92.90 Cr	150.96 Cr	216.27 Cr
Current Liabilities	-	58.29 Cr	86.59 Cr	118.97 Cr	150.01 Cr
Long Term Debt	-	2.07 Cr	74.48 L	25.34 Cr	56.40 Cr
Total Debt	-	32.50 Cr	34.00 Cr	77.10 Cr	108.51 Cr
Total Equity	-	222.55 Cr	262.63 Cr	282.43 Cr	329.23 Cr
Shares Outstanding	-	61.78 L	61.78 L	61.78 L	61.78 L

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	35.29 Cr	20.47 Cr	32.36 Cr	43.32 Cr
Investing Cash Flow	-	-27.02 Cr	-26.82 Cr	-69.68 Cr	-70.59 Cr
Financing Cash Flow	-	-1.08 Cr	-1.08 Cr	37.46 Cr	29.55 Cr
Capital Expenditure	-	-31.41 Cr	-28.52 Cr	-74.29 Cr	-89.85 Cr
Free Cash Flow	-	3.88 Cr	-8.06 Cr	-41.93 Cr	-46.53 Cr
Net Change in Cash	-	7.18 Cr	-7.43 Cr	13.95 L	2.27 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	48.7%	52.4%	50.5%	52.2%
Operating Margin %	-	8.7%	12.6%	5.8%	10.6%
Net Margin %	-	7.5%	12.4%	5.7%	9.6%
ROE %	-	9.2%	15.7%	7.5%	14.6%
ROCE %	-	10.3%	15.7%	6.8%	13.4%

Shareholding Pattern

Insiders

72.74%

Institutions

0.00%

Public Float

0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NGLFINE

No recent headlines available.

NGLFINE · Healthcare